期刊文献+

HBV转基因小鼠的解毒活力变化的研究 被引量:3

DECREASED DETOXIFICATION OF AFLATOXIN B1 IN HEPATITIS B VIRUS TRANSGENIC MICE
下载PDF
导出
摘要 AFB1和HBV是致肝癌的两个主要因素。研究表明AFB1与HBV有协同致肝癌作用,但其机理不明。方法利用HBV转基因小鼠模型,分析小鼠肝脏组织中的细胞色素P450酶的含量和活性,GSH和GST的含量和活性,并测定HBV转基因小鼠暴露于AFB1后血清AFB1┐白蛋白加成物的含量。结果加成物的含量在HBV转基因小鼠都较对照小鼠高,细胞色素P450酶含量明显降低而活性有所上升,GSH含量和GST酶活性都明显下降。结论HBV转基因小鼠的解毒代谢能力下降。HBV影响了小鼠的解毒代谢,使小鼠对AFB1敏感。 Aflatoxin B1 (AFB1)is activated to form AFB1 8,9 epoxide via cytochrome P450s.The epoxide can then be rendered innocuous via phase 2 enzymes(glutathione S transferases GSTs). The mechanistic role of human hepatitis B viurs(HBV) in liver tumorigenesis is unresolved.Methods:To determine whether HBV transgenic mice are more susceptible to the effects of AFB 1,livers from transgenic and control non transgenic mice were analyzed for the enzyme systems involved in metabolism. Results: The levels of liver cytochrome P450s and GSH and the activity of GSTs of the transgenic mice were significantly lower than nontransgenic mice( P <0 01).The activities of cytochrome P450 enzymes in the livers of transgenic mice were higher than those of non transgenic mice.After exposure to AFB1, the content of AFB1 albumin adducts in the sera of transgenic mice were higher than those of non transgenic mice at multiple timepoints over 24 hours. Conclusions:These data suggest that HBV decreases detoxification of AFB1 in the transgenic mice and are consistent with the synergy observed between HBV expression and hepatocarcinogenesis in animal models and epidemiological studies.
出处 《肿瘤》 CAS CSCD 北大核心 1997年第4期187-189,共3页 Tumor
基金 国家自然科学基金癌基因和相关基因国家重点实验室基金资助国家九.五攻关基金
关键词 代谢解毒 黄曲霉毒素 HBV 肝肿瘤 Metabolic detoxication Aflatoxin B1 Hepatitis B virus,Transgenic mice
  • 相关文献

同被引文献75

  • 1沈肖方,李建远,王海燕,王学波,靳绍华,刘芙君,刘运祥.IL-2 preS DNA疫苗免疫正常小鼠和HBV转基因鼠的免疫应答研究[J].中华微生物学和免疫学杂志,2004,24(11):914-918. 被引量:3
  • 2万曙光,励雁峰,张萍萍,万大方,钱耕荪,顾健人,成国祥,徐少甫.人乙肝病毒转基因小鼠肝脏形态观察和DNA图象分析初报[J].上海实验动物科学,1995,15(4):206-209. 被引量:3
  • 3赵蔚,陈红,彭炤源,李文刚,席宏丽,徐小元.双靶区反义RNA对乙型肝炎病毒转基因小鼠抗病毒疗效的研究[J].中华医学杂志,2005,85(49):3486-3490. 被引量:6
  • 4Yang PL, Althage A, Chung J, et al. Immune effectors required for hepatitis B virus clearance[J]. Proc Natl Acad Sci USA, 2010, 107(2) : 798-802.
  • 5Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection[J]. Science, 1999, 284 (5415): 825-829.
  • 6Chisari FV, Pinkert CA, Milich DR, et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state[J]. Science, 1985, 230 (4730): 1157-1160.
  • 7Babinet C, Farza H, Morello D, et al. Specific expression of hepatitis B surface antigen (HP, sAg) in transgenic mice[J]. Science, 1985, 230(4730) : 1160-1163.
  • 8Chisari FV, Filippi P, McLachlan A, et al. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice[J]. J Virol, 1986, 60(3): 880-887.
  • 9Guidotti LG, Matzke B, Schaller H, et al. High-level hepatitis B virus replication in transgenic mice[J]. J Virol, 1995, 69(10): 6158-6169.
  • 10Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice[J]. Proc Natl Acad Sci USA, 1994, 91(9): 3764-2768.

引证文献3

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部